RxDoctor Payments Data

Stefanie Remson

Nurse Practitioner · Henderson, NVNPI 1083981955

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,785 of the $6,515 with a category attached, or 88.8%. 20 manufacturers reported payments, led by Viiv Healthcare Company at 26.8% of the total. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,515in general payments, 2019–2025

Across 289 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$2K
  • Merck$1K
  • GSK$390
  • Astellas Pharma US Inc$351
  • Paratek Pharmaceuticals, Inc.$285
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$3906%
  • Food & beverage$5,78589%
  • Education$3405%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,515 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala210$884,339
TriumeqAbacavir/Dolutegravir/Lamivudi98$403,444
OdefseyEmtricitab/Rilpiviri/Tenof Ala50$219,872
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$108,688
GammakedImmune Globul G/Gly/Iga Avg 4617$103,276
IsentressRaltegravir Potassium36$75,310
Daptomycin18$56,694
TivicayDolutegravir Sodium15$37,234
DescovyEmtricitabine/Tenofov Alafenam11$32,413
Darunavir16$25,362
MounjaroTirzepatide18$18,455
ErtapenemErtapenem Sodium37$17,538
Fosamprenavir Calcium13$10,785
Breo ElliptaFluticasone/Vilanterol11$4,306
Rifampin48$3,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,520$1,025,440246 claims
Viiv Healthcare CompanyTriumeq, Tivicay$1,744$440,677113 claims
MerckIsentress$1,017$75,31036 claims
GSKBreo Ellipta$390$4,30611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →